LEGEND-2 Long-term Follow-up: Phase I Trial of LCAR-B38M CAR T-Cell Therapy in R/R MM

December 7-10, 2019; Orlando, Florida
Long-term follow-up of LEGEND-2 suggests LCAR-B38M CAR T-cell therapy highly active in patients with relapsed/refractory multiple myeloma.
Format: Microsoft PowerPoint (.ppt)
File Size: 188 KB
Released: December 13, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Ian W. Flinn, MD, PhD; Shaji Kumar, MD; and Farhad Ravandi, MD, discuss important presentations in hematologic malignancies from the virtual ASCO 2020 as reported by Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Shaji Kumar, MD Farhad Ravandi, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 23, 2020 Expired: September 22, 2021

Downloadable clinical resource from CCO includes a proposed 2020 treatment algorithm for myeloma

Shaji Kumar, MD Released: September 22, 2020

In this slideset from Clinical Care Options, Sarah A. Holstein, MD, PhD and Jonathan L. Kaufman, MD highlight key data for management of myeloma for veterans

Sarah A. Holstein, MD, PhD Jonathan L. Kaufman, MD Released: September 22, 2020

CCO commentary by Dr. Natalie Callander on the potential and the challenges of CAR T-cell therapy targeting BCMA in patients with multiple myeloma

Natalie S. Callander, MD Released: September 22, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue